Orthopediatrics CORP 8-K filings

OrthoPediatrics Corp. reported a 33% year-over-year increase in revenue for the second quarter of 2024, reaching $52.8 million, and reaffirmed its full-year revenue guidance.

OrthoPediatrics Corp. has entered into a private financing agreement with Braidwell LP, securing up to $100 million through a term loan and convertible notes.

OrthoPediatrics Corp. held its 2024 Annual Meeting of Stockholders on May 24, 2024, where shareholders voted on the election of directors, executive compensation, the 2024 Incentive Award Plan, and the appointment of the independent auditor.

OrthoPediatrics Corp. has adopted a new 2024 Incentive Award Plan, replacing the 2017 plan, to align the interests of directors, employees, and consultants with those of stockholders.

OrthoPediatrics Corp. outlines its strategic focus on pediatric orthopedics, highlighting consistent growth, innovative product development, and recent acquisitions in a new investor presentation.

OrthoPediatrics Corp. reported a 41% increase in first-quarter revenue and raised its full-year revenue guidance, driven by strong growth across its product lines and the acquisition of Boston Orthotics & Prosthetics.

OrthoPediatrics Corp. outlines its strategic focus on the pediatric orthopedic market, highlighting its growth, product innovation, and recent acquisitions in a new investor presentation.

OrthoPediatrics Corp. reported a 22% increase in full-year revenue to $148.7 million and a significant improvement in adjusted EBITDA to $5.0 million for 2023.